A Virtual Reality View: Individualizing the Management of Relapsed and/or Refractory Multiple Myeloma: Novel Combination Treatment Options and Sequencing Strategies

REGISTER NOW!
Already Registered?
SIGN IN

WEBCAST DATE

Thursday, May 2, 2019

6:00 PM Eastern    5:00 PM Central    4:00 PM Mountain    3:00 PM Pacific

PROGRAM FEATURES

• • Virtual Reality animations
  • iPads provided to enhance learning experience
  • Personalized posters

FACULTY

Ajay K. Nooka, MD, MPH, FACP
Associate Professor
Division of Bone Marrow Transplant
Winship Cancer Institute
Emory University School of Medicine
Atlanta, GA

Ajai Chari, MD
Associate Professor of Medicine
Hematology & Medical Oncology
Icahn School of Medicine at Mount Sinai
New York, NY

AGENDA

I. Multiple myeloma (MM): an overview
  a. Epidemiology
    i. Role of age
    ii. Role of ethnicity
  b. Disease pathophysiology
  c. Disease course: relapsed/refractory (R/R)
  d. Disease burden/effects on patient quality of life

II. Individualizing the sequencing of care for patients with R/R MM
  a. Disease-related considerations
    i. Nature of relapse (indolent vs aggressive)
    ii. Risk stratification
    iii. Genetics of initial and relapsed marrow
    iv. Disease burden (high vs low)
    v. Revised International Staging System (R-ISS) staging for MM (1 vs 2–3)

  b. Treatment-related factors
    i. Previous therapy
    ii. Regimen-related toxicity
    iii. Depth and duration of previous response, tumor burden at relapse

  c. Patient-related factors
    i. Renal insufficiency
    ii. Hepatic impairment
    iii. Comorbidities and frailty
    iv. Patient preferences

III. Novel therapeutic options for the treatment of R/R MM
  a. Recently-approved next-generation PIs and IMiDs
  b. MOAs and clinical trial efficacy and safety data for mAbs
  c. (VR Theme: MOA of elotuzumab)
  d. NCCN guideline recommendations
    i. Recommendations that include mAbs
    ii. (VR Theme: MOA of NCCN guideline "preferred" regimen recommendation [elotuzumab/lenalidomide/dexamethasone] and "other suggested" regimen recommendation [elotuzumab/bortezomib/dexamethasone])

IV. The role of physician-patient communication in R/R MM
  a. Evidence suggesting physician-patient communication barriers
  b. Strategies to improve physician-patient interactions

V. Case studies

VI. Conclusions

VII. Questions and answers

LEARNING OBJECTIVES

After completing the educational activity, learners should be better able to:

• Describe the MOAs and clinical profiles of novel treatment options for patients with R/R MM
• Individualize the selection and sequencing of novel drug combination therapies through multiple remissions and subsequent relapses based on disease-, treatment-, and patient-related factors
• Apply strategies that will improve communication, engagement, education, and decision making with patients with R/R MM and their health care providers

TARGET AUDIENCE

This initiative is designed to meet the educational needs of community and academic medical oncologists and advanced practitioners (NP/PA/PharmD) involved in the management of patients with MM.

ACCREDITATION STATEMENT

Med Learning Group is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENT

Med Learning Group designates this live activity for a maximum of 2.0 AMA Category 1 Credit(s)^TM. Physicians should claim only the credit commensurate with the extent of their participation in the live activity.

NURSING CREDIT INFORMATION

Purpose: This program would be beneficial for nurses involved in the care of patients with multiple myeloma.
Credits: 2.0 ANCC Contact Hours

CNE Accreditation Statement: Ultimate Medical Academy/CCM is accredited as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation. Awarded 2.0 contact hours of continuing nursing education of RNs and APNs

DISCLOSURE POLICY STATEMENT

In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Commercial Support, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in a MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.

DISCLOSURE OF UNLABELED USE

Med Learning Group requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

DISCLAIMER

Med Learning Group makes every effort to develop educational activities that are scientifically based.
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

For questions, please contact: Med Learning Group at info@medlearninggroup.com.

Contact Med Learning Group for privacy and confidentiality policy statement information at: http://www.medlearninggroup.com/privacy-policy/

AMERICANS WITH DISABILITIES ACT

Event staff will be glad to assist you with any special needs (eg, physical, dietary, etc.). Please contact Med Learning Group prior to the live event at info@medlearninggroup.com

Copyright © 2019 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.